Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic

ASSEMBLY BIOSCIENCES, INC.

2023-Q2 EPS reported -$0.69

Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.
Cash, cash equivalents and marketable securities $59.8M as of June 30, 2023; projected to fund ops through Q3 2024.
Herpesvirus candidate ABI-5366 entered GLP toxicology; IND/CTA submission planned for H1 2024.
Second development candidate nomination expected in 2023; additional candidate to enter clinic by year-end 2024.
Three abstracts accepted for 2023 International HBV Meeting in Kobe, Japan (Sept 19-23).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. reported the quarter ended June 30, 2023 results: net income $16.9 million, or $0.32 per basic and diluted share, EPS $0.32 per basic and diluted share.

Period: the quarter ended June 30, 2023
Net income: $16.9 million, or $0.32 per basic and diluted share
EPS: $0.32 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-040590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.